These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18372435)

  • 1. C-reactive protein, anti-C-reactive protein antibodies and clinical atherosclerosis.
    Rosenau BJ; Costenbader KH; Schur PH
    Vasc Med; 2008 Feb; 13(1):25-8. PubMed ID: 18372435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis.
    Quéméneur T; Martin-Nizard F; Kandoussi A; Kyndt X; Vanhille P; Hachulla E; Hatron PY; Fruchart JC; Duriez P; Lambert M
    Semin Arthritis Rheum; 2007 Dec; 37(3):149-55. PubMed ID: 17512573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome.
    Wetterö J; Nilsson L; Jonasson L; Sjöwall C
    Clin Chim Acta; 2009 Feb; 400(1-2):128-31. PubMed ID: 18973750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness.
    Pirro M; Vaudo G; Lupattelli G; Pasqualini L; Mannarino MR; Schillaci G; Alaeddin A; Paciullo F; Fallarino F; Bagaglia F; Mannarino E
    Life Sci; 2013 Sep; 93(8):338-43. PubMed ID: 23871987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L; Uzick M
    Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
    Burmeister JE; Miltersteiner DR; Campos BM
    J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between protein bound sialic acid and high sensitivity C-reactive protein in prehypertension: a possible indication of underlying cardiovascular risk.
    Sathiyapriya V; Selvaraj N; Nandeesha H; Bobby Z; Aparna A; Pavithran P
    Clin Exp Hypertens; 2008 Jul; 30(5):367-74. PubMed ID: 18633759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-reactive protein (CRP)-lowering agents.
    Prasad K
    Cardiovasc Drug Rev; 2006; 24(1):33-50. PubMed ID: 16939632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: in vivo and in vitro studies.
    Yip HK; Sun CK; Chang LT; Wu CJ; Chua S; Fu M
    Int J Cardiol; 2007 Oct; 121(3):253-60. PubMed ID: 17196684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice.
    Trion A; de Maat MP; Jukema JW; van der Laarse A; Maas MC; Offerman EH; Havekes LM; Szalai AJ; Princen HM; Emeis JJ
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1635-40. PubMed ID: 15920036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between inflammation, lipid and hemostatic factors in patients with stable angina.
    Sagastagoitia JD; Sáez Y; Vacas M; Narváez I; Sáez de Lafuente JP; Molinero E; Magro A; Lafita M; Santos M; Escobar A; Iriarte JA
    Thromb Res; 2007; 120(1):53-9. PubMed ID: 16916537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin.
    Hu WL; Qiao SB; Li JJ
    Cytokine; 2007 Dec; 40(3):201-6. PubMed ID: 18023360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aggressive statin therapy reduces the progression of atherosclerosis-- DMW15/2005].
    Taut V
    Dtsch Med Wochenschr; 2006 Mar; 131(9):460; author reply 460. PubMed ID: 16493575
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
    Michos ED; Blumenthal RS
    J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.